Diagnostic & Interventional Cardiology recently published the article, “Use of Catheter Reprocessing to Reduce Cath and EP Lab Costs”, that explores the challenges and opportunities found within the EP lab setting. The article notes that “growth in atrial fibrillation, combined with the increasing costs of procedures to address this demand, has triggered rapid growth in new EP technologies as an alternative to pharmaceutical treatment.”

With this growth are opportunities for hospitals and healthcare providers to align cardiology industry objectives with clinical and patient care goals. One way this can happen is through the use of reprocessed devices. The article reports that some “EP labs in America have saved more than $1 million per year” with reprocessing.

To read the full article, written by Lars Thording of Innovative Health (an AMDR member company), click here.